Phenylketonuria (PKU) is an inborn error of metabolism caused by deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH) which leads to high blood phenylalanine (Phe) levels and consequent damage of the developing brain with severe mental retardation if left untreated in early infancy. The current dietary Phe restriction treatment has certain clinical limitations. To explore a long-term nondietary restriction treatment, a somatic gene transfer approach in a PKU mouse model (C57Bl/6-Pah enu2 ) was employed to examine its preclinical feasibility. A recombinant adenoassociated virus (rAAV) vector containing the murine Pah-cDNA was generated, pseudotyped with capsids from AAV serotype 8, and delivered into the liver of PKU mice via single intraportal or tail vein injections. The blood Phe concentrations decreased to normal levels (p100 mM or 1.7 mg/dl) 2 weeks after vector application, independent of the sex of the PKU animals and the route of application. In particular, the therapeutic long-term correction in females was also dramatic, which had previously been shown to be difficult to achieve. Therapeutic ranges of Phe were accompanied by the phenotypic reversion from brown to black hair. In treated mice, PAH enzyme activity in whole liver extracts reversed to normal and neither hepatic toxicity nor immunogenicity was observed. In contrast, a lentiviral vector expressing the murine Pah-cDNA, delivered via intraportal vein injection into PKU mice, did not result in therapeutic levels of blood Phe. This study demonstrates the complete correction of hyperphenylalaninemia in both males and females with a rAAV serotype 8 vector. More importantly, the feasibility of a single intravenous injection may pave the way to develop a clinical gene therapy procedure for PKU patients.
Introduction
Phenylketonuria (PKU) (OMIM261600) is an autosomal recessive genetic disorder characterized by accumulation of the essential amino acid phenylalanine (Phe) in the body due to deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH; EC1. 14.16.1).
1,2 PAH converts Phe to tyrosine in the presence of molecular oxygen and the cofactor tetrahydrobiopterin (BH 4 ). High levels of accumulated Phe (4360 mM or 6 mg/dl) in PKU patients are toxic to the developing brain, and result in severe mental retardation if left untreated. Other abnormal clinical manifestations associated with PKU are growth failure, microcephaly, seizures, and hypopigmentation of skin, hair, and eye. The currently most effective treatment for PKU is a life long Phe-restricted diet, which will prevent severe mental retardation if initiated early in infancy following diagnosis after newborn screening. [3] [4] [5] However, this treatment has its own limitations: compliance is generally poor due to the unpalatable, offensive, artificial diet, particularly in adolescents and adults, and discontinuation of diet therapy is often associated with low intellectual achievement, and behavioral and psychosocial difficulties. [6] [7] [8] Moreover, women with PKU must maintain a strict Pherestricted diet before and during pregnancy to prevent severe fetal damage, including microcephaly, mental retardation, behavioral problems, and congenital heart defects, the so-called maternal PKU syndrome. 9 The long-term clinical outcome of the diet treatment is unknown since the early treated PKU patients are only in their forties. Last but not least, the PKU patients undergoing diet restriction have to modify their life style significantly compared with healthy people; consequently, this puts an additional heavy burden on the patient's family. Thus an alternative treatment for PKU is urgently needed, and somatic gene therapy provides a promising approach to completely eliminate the longterm Phe-restricted diet.
In the last decade, the adeno-associated virus (AAV) has emerged as one of the most promising gene transfer vectors for treatment of both inherited and acquired human diseases based on its unique characteristics, such as the ability to transduce both dividing and nondividing cells and to mediate long-term transgene expression without toxicity. 10 Preclinical experiments with AAV in animal models for different diseases have proven the long-term stable transgene expression in liver, muscle, and central nervous system. [11] [12] [13] [14] [15] [16] [17] Several early-phase clinical trials with AAV vectors have been initiated and shown to be safe. [18] [19] [20] [21] Among the at least eight different AAV natural serotypes discovered so far, AAV vector derived from serotype 2 (AAV2) has been the most extensive studied and widely used AAV vector in the past 20 years. However, neutralizing antibodies against AAV2 exist in a large human population, 22, 23 and relative transduction efficiency of AAV2 in liver is less than 10% in hepatocytes. 24 Nevertheless, the existence of alternative AAV serotypes, which showed distinct transduction profiles in terms of tissue tropism, may circumvent these two shortcomings and expand the usefulness of AAV. In particular, the recently isolated AAV serotype 8, which showed low pre-existing immunity in the human population, and its preferred tropism to liver, might become the top priority for future AAV applications in liver. 22, 25 In the past, different strategies have been evaluated to investigate the possibility of somatic gene therapy in a PKU mouse model, but none of them had a satisfactory outcome. 26 Recently, two reports demonstrated the potential to correct PKU in a mouse model by AAV serotype 2-and 5-mediated gene transfer into liver. 27, 28 However, route-independent, that is, tail-vein application, and long-term therapeutic effects in females were not achieved despite very high doses of rAAV vector administration (up to 10 14 viral particles per mouse). Since AAV serotype 2 and 5 have been shown to have a low efficiency in liver transduction, 12 alternative serotypes, as discussed above, might be employed for liverdirected gene transfer. Here, we show a long-term, administration-route and gender-independent therapeutic correction of PKU mice by hepatic gene transfer with a rAAV serotype 8 vector.
Results and discussion
A rAAV vector was constructed by inserting the murine Pah-cDNA into an AAV2 vector plasmid (provided by H Bü eler 17 ). This vector, pAAV2-PKU-5, contained the Pah-cDNA under the control of a modified CMV enhancer chicken b-actin (CBA) promoter, the woodchuck post-transcriptional regulatory element (WPRE) sequence to enhance gene expression, and an SV40 polyadenylation signal sequence flanked by inverted terminal repeats from AAV2 ( Figure 1 ). Pseudotyped rAAV with capsids from serotype 8, rAAV2-PKU-5/8, were produced in an adenovirus-free system in 293T cells by triple transient transfection protocol with the pAAV2-PKU-5 vector and helper plasmids 22 34 resulted in a complete deficiency of hepatic PAH activity (o0.02 mU/ mg; Table 1 ). In comparison, normal hepatic PAH activity in C57Bl/6 wild-type mice was 3.5070.64 mU/mg protein (see also Table 1 ). Phe concentrations of these PKU mice, collected from tail veins on Guthrie filter cards and measured by tandem mass spectrometry, were 17827333 mM (n ¼ 43). When comparing the Phe concentrations of male and female PKU mice, we found that the Phe concentrations in females were slightly but not significantly higher than in males (males: 16957385 mM, n ¼ 21; females: 18667256 mM, n ¼ 22; P-value 0.0997). This reflects to some extent the disagreement published by Mochizuki et al. 27 in comparison with the publication by Oh et al. 28 with regard to sex-dependent blood Phe concentrations in PKU mice (see also discussion below). 293T cells were infected with rAAV vectors at a multiplicity of infection (MOI) of 10 6 . PAH enzyme activity 31 of cell lines was measured 48 h after transduction, and of liver 8 weeks after rAAV vector injections via the portal vein (or age-matched wild-type control animals). The control vector rAAV-GFP was kindly provided by H Bü eler. 33 Gene therapy with AAV serotype 8 for PKU Z Ding et al changes of blood Phe concentrations after vector injection in both males and females. After 2 weeks, intraportal vein infusion, Phe levels decreased to normal values comparable to wild type (p100 mM); that is, males decreased from 12797160 to 82715 mM, and females from 1879786 to 80718 mM. Moreover, blood Phe concentrations monitored over a period of at least 42 weeks remained at normal levels of o100 mM (Figure 2a ). Although intraportal vein infusion is quite efficient for targeting the liver, it is a very invasive method for a clinical approach. Thus, as an alternative administration route, we tested intravenal tail injection of rAAV2-PKU-5/8 vectors. Considering that only small amounts of the injected rAAV vectors enter the liver, 2 Â 10 13 viral particles, a four-fold higher dose than for intraportal vein infusion, were injected via the tail vein of young adult PKU mice. Similarly as seen with portal vein injections, Phe concentrations decreased in 2 weeks from 19657367 to 97750 mM. Again normal levels o100 mM of blood Phe were maintained during the whole experimental period of at least 35 weeks, independent of the sex of the animals (Figure 2b ).
Owing to attenuated biosynthesis of melanin, hypopigmentation is one of the visible phenotypes of PKU, including mice bearing the homozygous Pah enu2 allele, and it was reported that restoration of hypopigmentation needs at least 10% of the PAH enzyme activity. 35, 36 This phenotype was reversed in C57Bl/6-PKU mice to wild type level after intraportal or tail vein infusion of rAAV2-PKU-5/8 vectors. Changes started from 2 weeks after injection and became indistinguishable from wild-type at around 8 weeks after vector application (only shown for intraportal injection in Figure 3 ).
Hepatic Pah-mRNA expression, PAH enzyme activity, and presence of PAH protein was determined 8 weeks after intraportal rAAV2-PKU-5/8 vector infusion in a sacrificed animal. Since the PKU mouse expresses mRNA (and mutant protein) from the Pah enu2 allele 26 (and CO Harding, personal communication), we can only compare the relative expression level which turned out to increase in AAV2-PKU-5/8-treated mice to 132% compared to untreated PKU mice (100%). 31 Regarding liver PAH activity, which was 3.5070.64 mU/mg protein in wild-type control mice and almost undetectable in untreated PKU (Pah enu2 ) mice (o0.02 mU/mg protein), increased to 3.3270.24 mU/mg protein in treated PKU mice (see also quantitative Taqman analysis, 37 and semi-quantitiative PCR followed by agarose gel separation and comparison to standard vector dilutions. Both methods yielded comparable results, as we found in liver of treated mice 340072605 vector genome copies per diploid genome with the Taqman analysis, and approximately 10 3 vector genome copies for liver with the semi-quantitative method. Furthermore, the lowest transduction of AAV2-PKU-5/8 was in brain with 875 vector genome copies per diploid genome, compared to 26711 in skeletal muscle, 20714 in lung, 27715 in heart, 2276 in spleen, and 1476 in kidney (Figure 4b) . Results from transduction rates with the semi-quantitative method were in agreement with this tissue distribution as we detected copies between 10 and 20 as judged from the agarose gel shown in Figure 4c . In summary, we found after injection of 5 Â 10 12 vector genomes per mouse approximately 10 3 rAAV copies per transduced hepatocyte which is comparable to Nakai et al. 25 that reported a transduction rate of around 620 copies in liver cells for 7.2 Â 10 12 vector genomes per injected mouse. Unfortunately, transduction rates of rAAV in liver of PKU mice were not reported for the treatments published by Mochiziki et al. 27 or Oh et al.
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Serum hepatic and renal parameters (alanine aminotransferase ALT, aspartate aminotransferase AST, and gamma-glutamyltranspeptidase gGT), as well as inflammation parameters (interleukin-12 (IL-12) and tumor necrosis factor-a (TNF-a)) did not show any significant increase at 4 and at 20 weeks after portal or tail vein injections (not shown). This indicated that there was neither liver damage nor toxicity in rAAV vector-treated mice, which is also in agreement with reports from others.
14, 25 We thus concluded that AAV serotype 8 is superior to serotype 2 or 5 vectors for liver transduction, and was efficient for gene transfer to correct liver PAH Gene therapy with AAV serotype 8 for PKU Z Ding et al deficiency. 22, 25 Furthermore, we did not see any significant titer of PAH antibody by ELISA detection in serum samples of AAV2-PKU-5/8 treated mice, whether they received virus via portal vein or intravenous injections (Figure 4d ). Although no evidence for tumorigenesis of AAV vectors in mice was found, 38 a potential oncogenic activity of the WPRE sequence upon recombinant viral therapy containing this DNA element was reported. 39 We performed with a limited number of our experimental mice (n ¼ 3) a careful inspection for tumors, including histological analysis of liver. Despite the fact that these mice had life-long therapy for PKU and harbored per hepatocyte up to 10 3 genomic copies of rAAV containing each a WPRE element, we did not find any indication for tumors.
It should be emphasized that the outcome in our experiments present several improvements over what Oh et al. and Mochizuki et al. had reported recently. In the paper by Oh et al. 28 it was observed that tail vein administration of rAAV-hPAH to PKU mice did not result in a significant decrease of plasma Phe. On the other hand, Mochizuki et al. 27 showed that Phe levels in females after intraportal vein infusion of rAAV-mPAH did not reach therapeutic ranges at a dose of 1 Â 10 13 viral particles per mouse. However, therapeutic ranges were achieved at a dose of 1 Â 10 14 viral genomes per mouse, that is, 20-fold higher than the rAAV2-PKU-5/8 vectors used in our experiments, but only for an initial period of 8 weeks. After that, Phe concentration started to rise and went beyond therapeutic range after 16 weeks. It was speculated that one of the reasons for the gender difference may be due to the sexual transduction difference of AAV2 and AAV5 vectors in liver. Indeed, liver transgene expression of rAAV vectors in males is five to 13-fold higher than in females, and this difference is mainly caused by androgens. 40 However, the detailed mechanism is unclear and other hepatic factors might also be involved since the difference occurred specifically in liver.
In parallel experiments we evaluated also a lentiviral vector carrying a liver-specific promoter to drive expression of the murine Pah-cDNA (ZD and BT, unpublished results). Following an intraportal (or tail) vein injection in the same PKU (Pah enu2 ) mice, we observed a marginal decrease but to our surprise no therapeutic levels of Phe whatsoever. This indicated, as noticed also by others, that lentiviral vectors may not be appropriate for liver gene transfer. 41, 42, 46 In summary, we showed that a single intraportal vein or tail vein administration of rAAV2-PKU-5/8 resulted in sustained therapeutic correction of the PKU mouse model, irrespective of the gender, and with no observed liver damage or toxicity associated with the rAAV transfer. The feasibility of a single i.v. injection paves the way for the development of a clinical gene therapy procedure for PKU patients, including optimization of dosage, and based on the proven superior efficacy for transduction by rAAV serotype 8 vectors.
Materials and methods

Recombinant AAV construction and production
The murine Pah-cDNA was amplified by PCR from plasmid pBlueMCK-bgmPAH (kindly provided by CO Harding 43 ) with primers containing the terminal restriction sites BamHI and EcoRI and cloned into pUC18 to generate pHSY106. The Pah-cDNA fragment was then excised by BamHI and EcoRI, filled-in by Klenow polymerase, and cloned into the PmlI site of the AAV2 vector plasmid (provided by H Bü eler 17 ) to generate plasmid pAAV2-PKU-5. Orientation of the Pah-cDNA and in-frame cloning were confirmed by DNA sequencing. Plasmid pAAV2-PKU-5 was transfected into 293T cells to produce adenovirus-free recombinant AAV, along with an adenoviral helper plasmid (gift from H Bü eler) and the packaging plasmid for AAV serotype 8 22 (provided by JM Wilson). The recombinant vectors were purified by two rounds of CsCl gradient centrifugation and concentrated with Amicon Ultra filters. 44 The physical particle titers were determined by Taqman analysis of WPRE sequence with the following primers and probe: 37, 45 forward primer, 5 0 -CCGTTGTCAGGCA ACGTG-3 0 ; reverse primer, 5-AGCTGACAGGT GGTG GCAAT-3 0 ; probe, 5 0 -FAM-TGCTGACGCAACCCCCAC TGGT-TAMRA-3 0 . Standard curve was generated by dilution of vector plasmids in the salmon sperm DNA (40 ng/ml) to increase the stability of plasmid dilutions.
Cell culturing, animal experiments, and blood analysis 293T cells were cultured in standard DMEM medium supplemented with 10% fetal bovine serum and antibiotics. All animal experiments were approved by the State Veterinary Office of Zurich and carried out according to the guideline of the Swiss Law of Animal Protection. The Pah enu2 allele was crossed into C57BL/6 background, and the genotype was identified by PCR and Alw26I restriction endonuclease digestion according to the method published by McDonald et al. 34 For gene therapy experiments, 8-10 weeks old adult male or female mice were anesthetized with isoflurane, and rAAV particles, dissolved in standard PBS solution, were injected into portal or tail veins using a 1 ml syringe with 30-gauge needle. For Phe monitoring, blood samples were collected from tail vein on Guthrie filter cards at different time points, and Phe (and Tyr) concentrations were determined by tandem mass spectrometry. The retro-orbital bleeding technique was used to collect large volume blood (200 ml) to detect anti-PAH antibody and to measure the liver enzymes ALT, AST and gGT.
PAH enzyme assay and Western analysis
PAH enzyme activity in liver homogenates was measured according to our published method. 31 For Western analysis, equal amount of homogenized liver lysates (10 mg) from wild-type or PKU (homozygous Pah enu2 ) mice untreated or treated with AAV vectors were separated on a 4-12% gradient SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was blocked with 10% nonfat milk, washed with standard TBS-Tween-20, and probed with a rabbit anti-PAH antibody (dilution 1:1000). For detection, an alkaline-phosphatase conjugated goat anti-rabbit IgG (BioRad) was applied, and the NBT/BCIP (Roche) solution was finally added to develop the color reaction.
DNA and RNA analysis
The number of AAV vector genomes per cell from different tissues was determined by quantitative Taqman-PCR analysis with primers and probes corresponding to 0 . Genomic DNA from different mouse tissues (liver, heart, brain, kidney, lung, muscle, and spleen) was isolated using the DNeasy kit (Qiagen AG) following the provided instructions. For analysis, 100 ng of genomic DNA was used as template. Dilutions of the rAAV vector plasmid were used to generate a standard curve for determination of vector genome copies. PCR was carried out at the standard condition for ABI Prism 7700 and data were analyzed with Sequence Detection System (Applied Biosystems).
Transduction rate of rAAV in the same tissues of virus treated mice was also determined with a semi-quantitative PCR method that was performed in a 50 ml reaction with 100 ng genomic DNA as template. The WPRE sequence (600 bp) was amplified with the following primers: forward 5 0 -TGAGGAGTTGTGGCCCGTTG-3 0 and reverse 5 0 -AGGGAGATCCGACTCGTCTG-3 0 . GAPDH was included as a internal control with the following primers: forward 5 0 -ACTGGCATGGCCTTCCG-3 0 , reverse 5 0 -CAGGCGGCACGTCAGATC-3 0 . PCR reactions were performed at two different number of cycles, 25 and 35, to identify high copy and low copy sequences.
To determine relative Pah-mRNA expression, 20-30 mg of mouse liver tissue was used for RNA isolation according to the manufacturer's protocol (QIAmp RNA Blood Mini Kit from Qiagen). Random primed cDNA was prepared from 1 mg total RNA using the Reverse Transcription System from Promega. Quantitative PCR was performed using Taqman technology and an ABI Prism 7700 sequence detector and the TaqMan Universal PCR Master Mix (Applied Biosystems). Primers and probe were designed as following: Forward primer: Detection of antibody against PAH by ELISA Serum samples were collected by retro-orbital bleeding of anesthetized animals. Direct-ELISA was employed to determine putative anti-PAH antibodies according to a published method. 47 Briefly, wells of micro titer plates were coated over night at 41C with 500 ng recombinant PAH protein in PBS buffer, and then treated with blocking solution (0.25% BSA, 0.05% Tween-20). After washing with PBS, 0.1 ml of serum samples diluted from 1:100 to 1:10 000 in blocking solution were added to the wells. After incubation for 1 h at room temperature, 0.1 ml HRP conjugated anti-mouse IgG (1:10 000, Sigma) was added to each well, incubated for 30 min at room temperature, and after extensive washing 0.1 ml of OPD substrate (Sigma Fast OPD tablet) was added and incubated for 10 min. The reactions were stopped by adding 0.1 ml of 4.5 N H 2 SO 4 . Absorbance was measured at 490 nm with a microplate reader. As a positive control, the polyclonal rabbit anti-PAH antibody was used as primary antibody, and a HRP conjugated anti-rabbit antibody the second antibody for detection.
